FDA perspectives on potential microarray-based clinical diagnostics

FDA perspectives on potential microarray-based clinical diagnostics

<p>Abstract</p> <p>The US Food and Drug Administration (FDA) encourages the development of new technologies such as microarrays which may improve and streamline assessments of safety and the effectiveness of medical products for the benefit of public health. The FDA anticipates tha...

Full description

Bibliographic Details
Main Authors: Težak Živana, Ranamukhaarachchi Daya, Russek-Cohen Estelle, Gutman Steven I
Format: Article
Language:English
Published: BMC 2006-01-01
Series:Human Genomics
Subjects:
microarray
<it>in vitro </it>diagnostics
FDA
gene expression
genotyping
array comparative genomic hybridisation (array CGH)
Online Access:http://www.humgenomics.com/content/2/4/236

Internet

http://www.humgenomics.com/content/2/4/236

Similar Items